Merck & Co., Inc. (MRK)
Merck & Co., Inc.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Merck is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- The stock has been climbing and sits near the top of its range for the year.
- Worth watching
- Its growth over the past year trails most other healthcare companies.
Analyst price target
~12-month · 25 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 73,000
- Headquarters
- Rahway, NJ
Similar stocks
What’s behind the score
Valuation
P/E 115.8 — lower than 0% of Healthcare peers
P/B 8.6 — lower than 21% of Healthcare peers
P/S 5.4 — lower than 43% of Healthcare peers
EV/EBITDA 14.1 — lower than 53% of Healthcare peers
EV/Revenue 6.1 — lower than 43% of Healthcare peers
PEG 2.7 — lower than 7% of Healthcare peers
FCF yield 4.2% — higher than 66% of Healthcare peers
Profitability & quality
Gross margin 75.9% — higher than 87% of Healthcare peers
Operating margin -0.2% — higher than 7% of Healthcare peers
Net margin 4.8% — higher than 30% of Healthcare peers
ROE 7.0% — higher than 33% of Healthcare peers
ROA 11.9% — higher than 83% of Healthcare peers
Free cash flow is 478% of reported net income
Financial health
Debt/equity 1.3 — lower than 15% of Healthcare peers
Current ratio 1.32 — higher than 38% of Healthcare peers
Quick ratio 0.74 — higher than 34% of Healthcare peers
Cash/debt 0.13 — higher than 24% of Healthcare peers
Debt/EBITDA 1.87 — lower than 66% of Healthcare peers
Growth
Revenue growth 5.1% YoY — higher than 23% of Healthcare peers
Ownership & investor activity
Payout ratio 266.7% — atypical vs Healthcare peers
Net insider selling, -3.6% of insider shares
Institutions net sold, -12.4% of shares held
Insiders hold 0.1% of shares outstanding
1.1% of float sold short
Momentum
Above its 50- & 200-day averages
85% of the way from its 52-week low to high